High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study
Jasmine Yee, Joanne M. Carson, Behzad Hajarizadeh, Joshua Hanson, James O’Beirne, David Iser, Phillip Read, Anne Balcomb, Joseph S. Doyle, Jane Davies, Marianne Martinello, Philiipa Marks, Gregory J. Dore, Gail V. Matthews, the REACH‐C Study Group – 1 November 2021 – Australia was one of the first countries with unrestricted access to government subsidized direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus.